5 citations
,
August 2024 in “Skin Research and Technology” This study found that KLB and EIF3C are important in the progression of vitiligo and AA, suggesting they could be biomarkers and early diagnostic targets.
56 citations
,
January 2021 in “Clinical and Experimental Medicine” This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.
55 citations
,
October 2019 in “Dermatology and therapy” This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.
290 citations
,
December 2017 in “Journal of The American Academy of Dermatology” This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.
74 citations
,
May 2016 in “Current opinion in pediatrics, with evaluated MEDLINE/Current opinion in pediatrics” This review identifies shared interferon gamma-driven immune pathways in vitiligo and alopecia areata, revealing potential targets for new treatments, but reports no clinical results.
36 citations
,
May 2011 in “Dermatologic therapy” This review discusses topical and intralesional treatments for alopecia areata, providing a management strategy based on patient age and disease severity, but reports no new clinical results.